2, Aoyuan Meigu 000615: the acquisition of medical beauty institutions in Zhejiang Liantianmei 55% stake, Liantianmei two-year commitment to the cumulative net profit of not less than $ 157 million, the company's two-year net profit consensus is expected to be 123 million, 220 million yuan, a cumulative total of about 45% of the company's net profit.
3, Longzi 002612: medical beauty industry leader, holding "Milan Park Yu", "crystal skin medical beauty" and "high life medical beauty" three major domestic medical brand, strategic investment in South Korea's famous medical beauty services. The company has invested strategically in DMG, a famous medical beauty service group in South Korea; initially formed a large plastic surgery hospital in Chengdu and Xi'an, two core cities in the west, plus a number of small chain outpatient clinics/clinics in the system of medical beauty organizations; in 18 years, the medical beauty revenue of 479 million yuan, accounting for 18.01% of the revenue.
4, ha Sanlian 002900: the company produces medical sodium hyaluronate repair patch, used for wound healing and skin repair.
5, Xinhua Jin 600735: subsidiary Qingdao Li Baijian involved in the field of plastic surgery.
6, Bethanie 300957: subsidiary Kunming Winona is mainly engaged in medical beauty services, specifically including laser, micro-needle and other beauty services.
What are the leading pharmaceutical stocks?
Domestic generic drug leading stocks: Hengrui Pharmaceuticals, East China Pharmaceuticals, Huahai Pharmaceuticals, Puli Pharmaceuticals, Jingxin Pharmaceuticals, Xinlitai.
1, Hengrui Medicine
Jiangsu Hengrui Medicine Co., Ltd. is approved by the People's Government of Jiangsu Province, by the Lianyungang Hengrui Group Co., Ltd. and other five initiators in April 1997 *** with the establishment of joint-stock limited company, is the largest anti-tumor drug research and production base.
2, East China Pharmaceutical
Hangzhou East China Pharmaceutical Group Company formerly known as Zhejiang Pharmaceutical Factory, founded in 1952, later renamed Hangzhou Second Pharmaceutical Factory, Hangzhou East China Pharmaceutical Factory.
On December 16, 1992, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, which has developed into a joint-stock enterprise--Huadong Pharmaceuticals Co., Ltd. and four Sino-foreign equity joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co.) and more than 10 other holding pharmaceutical enterprises.
3, Huahai Pharmaceutical
Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989, its predecessor for the Linhai City flood bridge synthetic chemical plant, in January 2001 the whole change was set up as Zhejiang Huahai Pharmaceutical Co.
In March 2003, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceuticals, stock code: 600521.
4, Puli Pharmaceutical
Hainan Puli Pharmaceutical Co., Ltd. was founded in 1992, is specializing in the research and development of chemical pharmaceutical preparations, production and sales of high-tech enterprises, has been through the China's pharmaceutical enterprises internationalization of the preparations of the pilot enterprise certification. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.
5, Jingxin Pharmaceutical
Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974, has developed into a national key high-tech enterprises, China's top 100 pharmaceutical companies, in July 2004, successfully listed on the Shenzhen Stock Exchange.
6, Xinlitai
Shenzhen Xinlitai Pharmaceutical Co., Ltd. is approved by the Ministry of Commerce of the People's Republic of China *** and the Ministry of Commerce "Ministry of Commerce on the consent of Shenzhen Xinlitai Pharmaceutical Co., Ltd. restructuring into a sino-foreign equity joint venture approved by the Ministry of Commerce" (business capital approved by the Ministry of Commerce [2007] No. 1016), and to obtain the Ministry of Commerce issued by the "People's Republic of China *** and the State of Taiwan, Hong Kong and Macao investment enterprises approved by the certificate". Certificate".